A phase II study of irinotecan alternated with five days bolus of 5- fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

Annals of Oncology

Volumn 9, Issue 11, 1998, Pages 1199-1204

  Van Cutsem, E ^a   Pozzo, C ^b   Starkhammar, H ^c   Dirix, L ^d   Terzoli, E ^e   Cognetti, F ^e   Humblet, Y ^f   Garufi, C ^e   Filez, L ^a   Gruia, G ^g   Cote, C ^g   Barone, C ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CATHOLIC UNIVERSITY   (Italy)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Rhone Poulene Rorer ^*  (France)

Author keywords

Alternating combination; Bolus fluorouracil; CPT 11; First line chemotherapy; Irinotecan; Metastatic colorectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 7844220589     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008478405634     Document Type: Article

References (26)

1. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in L-hemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
2. Shimada Y, Yoshino M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative. in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
3. Rothenberg ML, Eckardt J, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-35.
4. Pitot HC, Wender DB, O'Connell MJ et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-9.
5. Van Cutsem E, Rougier P, Droz JP el al. Clinical benefit of irinotecan (CPTII) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997; 16: A950 (Abstr).
6. Cunningham D, Pyrhönen S, James R et al. A phase III multicenter randomized study of CPT-II versus supportive care alone in patients with 5-FU-resistant metastatic colorectal cancer. Proc Am Soc Clin Oncol 1998; 17, AI (Abstr).
7. Van Cutsem E, Bajetta E, Niederle N et al. A phase III multicenter randomized trial comparing CPT-II to infusional 5-FU regimen in patients with advanced colorectal cancer after 5-FU. Proc Am Soc Clin Oncol 1998; 17: A256 (Abstr).
8. Conti J, Kemeny NE, Saltz LB et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-15.
9. The Nordic gastrointestinal tumor adjuvant project. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 1992; 10: 904-11.
10. Scheithauer W, Rosen H, Kornek GV et al. Randomized comparison of combination chemotherapy plus supportive care or supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-5.
11. Buroker TR, O'Connell MJ, Wieand HS et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14-20.
12. Leichman CG, Fleming TR, Muggia FM el al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-11.
13. De Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808-15.
14. Aranda E, Diaz-Rubio E, Cervantes A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998; 9: 727-31.
15. Moertel C. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-42.
16. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
17. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leueovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
18. Sobrero AF, Asehele C, Bertino JR. Fluorouracil in colorectal cancer a take of two drugs: Implications for biochemical modulation. J Clin Oncol 1997; 15: 368-81.
19. Glimelius B, Jakobsen A, Graf W et al. Bolus injection (2-4 min) versus short-term (10 20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomized trial. Eur J Cancer 1995; 5: 674-8.
20. The Meta-analysis Group in Cancer. Effiency of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
21. Rothenberg ML. Pazdur R, Rowinski EK et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-II) and 5-FU. LV in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997. 16: A944 (Abstr).
22. Savarese D, Hsieh CC, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997; 15: 2981-95.
23. Saltz L, Kanowitz J, Kemeny N et al. Phase I clinical and pharmacokinetic study of irinotecan. fluorouracil and leukovorin in patients with advanced solid tumours. J Clin Oncol 1996; 14: 2959-67.
24. Ducreux M, Rougier Ph, Ychou M et al. Phase I II study of escalating dose of CPT-II in combination with LV5 FU2 (De Gramont regimen) every two weeks in the treatment of colorectal cancer after 5-FU failure. Proc Am Soc Clin Oncol 1997; 16: A234 (Abstr).
25. Vanhoefer U, Harstrick A, Achternath W et al. Phase I study of a weekly schedule of irinotecan (CPT-II). high-dose folinic acid and 5-fluorouracil as first-line chemotherapy in metastatic colorectal cancer: Final results. Proc Am Soc Clin Oncol 1998; 17: A202 (Abstr).
26. Van Cutsem E, Cunningham D, Ten Bokkel-Huinink W et al. Clinical activity and benefit of irinotecan (CPT-II) in patients with colorectal cancer truly resistant to 5-FU. Eur J Cancer (in press).